(Total Views: 546)
Posted On: 01/24/2021 10:27:20 AM
Post# of 148906
Babaji,
We have several patients for some months now.
If I recall rightly, first patient was injected on Sept 27, 2019. NP MIL as well was injected Nov 25, another other in January 3 and 7 (the one on the 3rd stopped treatment).
We received P2 protocol approval from FDA for basket trial (22 Solid Tumor Cancers) on Feb 21, 2019 and treated the first patient on April 15 (MBC).
NP as referred to: "6 patients in trial and several on wait" in one of the conferences, in another he mentioned: "we enrolled so quickly, 11 patients, will follow very carefully. " and Dr. Kelly on 10/20/20 conference referring to basket trial: "We have 12 patients enrolled. We will see how results pan out."
Further on Nov 5, 2020: basket has 14 patients.
Latter on:
So, there is data out there ... I am particularly interested on learning about the CTC and CAML counts progression. This is critical as these are a very good proxy measurement of metastasis progression. If we can slow or stop this is like saying we have increased OSRs substantially and we have a "wonder drug".
We have several patients for some months now.
If I recall rightly, first patient was injected on Sept 27, 2019. NP MIL as well was injected Nov 25, another other in January 3 and 7 (the one on the 3rd stopped treatment).
We received P2 protocol approval from FDA for basket trial (22 Solid Tumor Cancers) on Feb 21, 2019 and treated the first patient on April 15 (MBC).
NP as referred to: "6 patients in trial and several on wait" in one of the conferences, in another he mentioned: "we enrolled so quickly, 11 patients, will follow very carefully. " and Dr. Kelly on 10/20/20 conference referring to basket trial: "We have 12 patients enrolled. We will see how results pan out."
Further on Nov 5, 2020: basket has 14 patients.
Latter on:
Quote:
The company said they needed 5 stage 4 patients that lived longer than 6 months to have the data they needed to approach the FDA about a BTD in their cancer basket trial. The company indicated there were a total of 9 patients that fit the criteria, and that those patients had zero CTC’s and very low CAML levels.
So, there is data out there ... I am particularly interested on learning about the CTC and CAML counts progression. This is critical as these are a very good proxy measurement of metastasis progression. If we can slow or stop this is like saying we have increased OSRs substantially and we have a "wonder drug".
(7)
(0)Scroll down for more posts ▼
